<DOC>
	<DOCNO>NCT00108511</DOCNO>
	<brief_summary>The purpose study examine role glycosylphosphatidylinositol-specific phospholipase D ( GPI-PLD ) triglyceride metabolism .</brief_summary>
	<brief_title>Effect Gemfibrozil Serum Glycosylphosphatidylinositol ( GPI ) Phospholipase D Triglycerides</brief_title>
	<detailed_description>Increased fast serum triglyceride level associate increase risk coronary artery disease . However , triglyceride level postprandial state sensitive marker coronary artery disease . Postprandial elevation triglyceride result decrease catabolism triglyceride-rich lipoprotein , i.e . chylomicron low density lipoprotein ( VLDL ) . This lead accumulation atherogenic remnant triglyceride-rich lipoprotein . Although fast triglyceride best predictor postprandial triglyceride , difference fast triglyceride partially account variation magnitude postprandial triglyceride . Recently , identify new protein involve triglyceride-rich lipoprotein catabolism , glycosylphosphatidylinositol-specific phospholipase D ( GPI-PLD ) . We show elevated level GPI-PLD associate increase fast triglyceride level . Serum GPI-PLD associate high density lipoprotein ( HDL ) fast state exchange onto VLDL postprandial state . Hepatic GPI-PLD decrease triglyceride-rich lipoprotein catabolism liver . Hepatic serum GPI-PLD level decrease peroxisome proliferator receptor ( PPAR ) alpha agonist treatment , also reduce fast postprandial triglyceride . The central hypothesis application variation GPI-PLD expression account portion difference fast postprandial triglyceride among human . The objective proposal determine role GPI-PLD regulate fast triglyceride post-prandial hypertriglyceridemia human . This accomplish conduct double blind , placebo control study human examine effect gemfibrozil fast postprandial triglyceride relationship variation change GPI-PLD gemfibrozil . Our specific objective : - 1a ) Determine extent variation GPI-PLD account difference fast postprandial triglyceride - 1b ) Establish degree lower fast postprandial triglyceride gemfibrozil account change GPI-PLD . - 2 ) Quantify change serum GPI-PLD distribution GPI-PLD among lipoprotein postprandial state . This first prospective bench-to-bedside study examine role GPI-PLD triglyceride metabolism . This proposal first humans examine 1 ) role novel protein , GPI-PLD , triglyceride metabolism , 2 ) effect gemfibrozil , drug currently use clinically low triglyceride level , GPI-PLD level human . It expect result study increase understand triglyceride metabolism develop new information understanding regulation GPI-PLD relationship triglyceride metabolism .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Gemfibrozil</mesh_term>
	<criteria>Age &gt; 18 &lt; 75 Fasting triglyceride &gt; 150 mg/dl Fasting triglycerides &gt; 600 mg/dl LDL &gt; 130 mg/dl Concurrent lipid lower therapy Known hypersensitivity gemfibrozil Alcohol intake &gt; 30 gm/day ( 2 drinks/day ) Fasting glucose &gt; 125 mg/dl know type 2 diabetes AST ALT &gt; 2.0 x upper limit normal Creatinine : men &gt; 1.4 mg/dl , woman &gt; 1.3 mg/dl Cancer treatment past 5 year ( unless cure ) Infectious disease include HIV tuberculosis Significant cardiac disease past 6 month ( myocardial infarction , coronary artery bypass graph , angioplasty , class 3 4 congestive heart failure , leave bundle branch block , third degree AV block ) Uncontrolled hypertension ( systolic blood pressure [ SBP ] &gt; 180 diastolic blood pressure [ DBP ] &gt; 105 mm Hg ) Anemia ( hematocrit &lt; 40 % men , &lt; 35 % woman ) Any significant systemic disease medication could interfere tolerance medication outcome Any indication participant unable adhere protocol Unable give inform consent Pregnant breastfeeding female female plan become pregnant participating study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>lipoprotein</keyword>
	<keyword>triglyceride</keyword>
	<keyword>serum GPI-PLD ( glycosylphosphatidylinositol-specific phospholipase D )</keyword>
</DOC>